Figure 2
Progression-free survival by BIM and MTOR mRNA expression levels in the training and validation cohort of patients
(a).Progression free survival to erlotinib according to BIM mRNA levels for the 27 erlotinib treated patients of the training cohort. Median PFS was 18.5 months (95%CI 9.7-NR) for the nine patients with high BIM (red line) and 3.6 months (95%CI 1.9–10.4) for the 18 patients with low BIM mRNA expression (blue line); P = 0.0145; (b) Progression-free survival by BIM and MTOR mRNA levels in 23 EGFR-mutant erlotinib-treated NSCLC patients of the training cohort whose BIM and MTOR mRNA could be evaluated. Median PFS was 6.9 months (95%CI 0.1–18.8) for the nine patients (G1) with low/intermediate BIM and MTOR and 4.2 months (95%CI 1.6-10.4) for seven patients (G2) with low/intermediate BIM and high MTOR. Median PFS was NR (95%CI 9.7-NR), for five patients (G3) with high BIM and low/intermediate MTOR and 9.7 months (95%CI NR) for the only two patients (G4) with high BIM and MTOR.; P = 0.0894. (c) Progression free survival to EGFR TKIs according to BIM mRNA levels in the 19 EGFR-mutant patients of the validation cohort. Median PFS was 15.0 months, (95% CI, 2.6–22.0) in the seven patients with high BIM (red line) and 9.2 months, (95% CI, 5.4-14.1) for the 12 patients with low BIM mRNA expression (blue line); P = 0.02. (d) Progression-free survival by BIM and MTOR mRNA levels in 19 EGFR-mutant NSCLC patients of the validation cohort, treated with EGFR TKIs, whose BIM and MTOR mRNA could be evaluated. Median PFS was 9.9 months (95%CI 5.4–14.1) for the 11 patients (G1) with low/intermediate BIM and MTOR and 8.2 months (95%CI NR) for one patient (G2) with low/intermediate BIM and high MTOR. Median PFS was 18.5 months (95%CI 14.2–53.1), for four patients (G3) with high BIM and low/intermediate MTOR and 13.0 months (95%CI 2.6–15.8) for the three patients (G4) with high BIM and MTOR; P = 0.0939. Note: BIM expression levels were divided into high (>2.96), low (<1.83) or intermediate (1.83–2.96). MTOR expression levels were divided into high (>1.97), low (<0.91) or intermediate (0.91–1.97).
